Investment Thesis
Beta Bionics demonstrates strong top-line revenue growth (+53.9% YoY) and healthy gross margins (59.5%), indicating a viable product offering in the medical device sector. However, the company is deeply unprofitable with severe operating losses (-$24.3M) and negative free cash flow (-$25.2M), while net losses worsened 33.7% YoY despite revenue growth. At current burn rate and $30.2M cash position, the company faces a critical need to achieve profitability within 12-15 months or require significant capital infusion.
Strengths
- Strong revenue growth momentum at 53.9% YoY indicates market demand
- Healthy gross margin of 59.5% demonstrates strong product pricing power and unit economics
- Excellent liquidity position with current ratio of 10.69x and minimal debt provides runway for operations
Risks
- Severe operating losses (-$24.3M) despite growing revenue indicates runaway operating expenses and poor cost control
- Negative free cash flow of -$25.2M with only $30.2M cash creates sustainability concerns within 12-15 months
- Deteriorating bottom-line performance (net income down 33.7% YoY) despite top-line growth suggests scaling challenges and inability to leverage revenue growth into profitability
Key Metrics to Watch
- Operating margin trajectory and path to breakeven
- Operating cash flow trends and monthly burn rate
- Revenue per unit and gross profit growth relative to headcount expense growth
Financial Metrics
Revenue
27.6M
Net Income
-21.9M
EPS (Diluted)
$-0.49
Free Cash Flow
-25.2M
Total Assets
304.4M
Cash
30.2M
Profitability Ratios
Gross Margin
59.5%
Operating Margin
-87.9%
Net Margin
-79.3%
ROE
-8.1%
ROA
-7.2%
FCF Margin
-91.3%
Balance Sheet & Liquidity
Current Ratio
10.69x
Quick Ratio
9.67x
Debt/Equity
0.00x
Debt/Assets
10.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-29T13:12:52.203210 |
Data as of: 2026-03-31 |
Powered by Claude AI